Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioblastoma × carotuximab × Clear all

Phase

Status

Sponsor Class

NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hemangiosarcoma 2 Choriocarcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Trophoblastic Tumor, Placental Site 1 Sarcoma 1 Ovarian Neoplasms 1 Glioblastoma 1 Gestational Trophoblastic Disease 1 Fallopian Tube Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Adult Solid Tumor 1

Interventions

Temozolomide 86 Bevacizumab 37 Radiotherapy 34 Lomustine 18 Radiation 16 Surgical Procedures, Operative 8 Carboplatin 8 pembrolizumab 7 Irinotecan 7 Carmustine 7 Nivolumab 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Flucytosine 6 vocimagene amiretrorepvec 5 depatuxizumab mafodotin 5 IL13-PE38 5 ABT-414 5 veledimex 4 sargramostim 4 NVP-BKM120 4 Gemcitabine 4 Dianhydrogalactitol 4 Cyclophosphamide 4 Chlorotoxin 4 Aminolevulinic Acid 4 selinexor 3 rindopepimut 3 olinvacimab 3 enzastaurin 3 Valacyclovir 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01564914 2019-06-12

105GM201

Tracon Pharmaceuticals Inc.

Phase 2 Completed

22 enrolled 11 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡